F ever is considered to be an adaptive response to infection, and in vitro and animal studies have shown that elevated temperatures augment several aspects of humoral and cellular immunity (1) . Yet, 20% of patients with sepsis present to the hospital with hypothermia rather than fever. These patients have twice the mortality of febrile patients even after accounting for factors such as age, disease severity, and comorbidities (2) . Although there are limited data to explain why these patients have worse outcomes, clear evidence links body temperature to infection risk. Clinical studies have demonstrated increased rates of surgical wound infections in hypothermic perioperative patients, and a recent meta-analysis showed an association between therapeutic hypothermia and sepsis in post-cardiac arrest patients (3, 4) . Additionally, a trial of systemic hypothermia in neonates with hypoxic ischemic encephalopathy found persistently depressed levels of total leukocytes and lymphocytes in patients who were cooled (5) .
To date, most clinical investigations of the effect of hypothermia on immune function have been limited to patients undergoing induced therapeutic hypothermia rather than in patients with sepsis presenting with spontaneous hypothermia. Only two previous studies have attempted to assess the immune status of hypothermic septic patients. Marik and Zaloga et al (6) found no differences in circulating levels of interleukin-6, tumor necrosis factor (TNF)-α, or soluble TNFα receptors between hypothermic and febrile septic patients, whereas Arons et al (7) observed increased plasma levels of interleukin-6 and TNF-α as well as increased urinary excretion of cyclooxygenase-derived lipid mediators in hypothermic patients, suggesting a dysregulated inflammatory response. It is unknown whether hypothermic patients exhibit immune dysfunction that is not apparent with quantitative cytokine measurements.
Sepsis activates both proinflammatory and anti-inflammatory mechanisms and can lead to extended periods of immunosuppression (8) . One feature of sepsis-induced immunosuppression is apoptotic loss of immune cells, including T and B cells. Persistent lymphopenia has been associated with increased risks of mortality and nosocomial infection (9, 10) . Although patients treated with induced therapeutic hypothermia have been shown to develop lymphopenia (5), investigation of lymphopenia as a potential link between spontaneous hypothermia and increased mortality in patients with sepsis has not been performed. Thus, the objective of this study was to examine the relationship between hypothermia and persistent lymphopenia in patients with sepsis. We hypothesized that patients who presented with hypothermia within 24 hours of sepsis diagnosis would be more likely to develop persistent lymphopenia than nonhypothermic patients.
MATERIALS AND METHODS

Study Design, Setting, and Population
This was a post hoc analysis of a retrospective cohort study conducted at a 1,200-bed university-affiliated hospital between January 1, 2010, and July 31, 2012. It was approved by the Human Research Protection Office at our institution with waiver of informed consent. All patients with positive blood cultures drawn within 5 days of admission to the hospital and a diagnosis of sepsis were eligible for inclusion. Sepsis was diagnosed by the presence of at least two systemic inflammatory response syndrome (SIRS) criteria within 24 hours of the time the positive culture was collected (11) . Exclusion criteria included diagnosis of immunological disease or treatment with immunosuppressant medication within 6 months prior to or during the hospitalization (Supplemental Table 1 , Supplemental Digital Content 1, http:// links.lww.com/CCM/B213).
Patients were divided into two cohorts, hypothermic or nonhypothermic, based on their lowest body temperature within 24 hours of sepsis diagnosis (identified by the time of their first positive blood culture). Hypothermia was defined as a temperature less than 36.0°C, consistent with the definition of hypothermia in the SIRS criteria (11) .
Data Collection
Baseline demographics, daily leukocyte counts, and clinical outcomes were collected by a research assistant blinded to the patients' temperatures. The first 24-hour period following the culture collection time was considered to be day 1; the next 24-hour period, day 2; etc. If multiple leukocyte counts were collected in a 24-hour period, the mean value was reported. Lymphopenia was defined as an absolute lymphocyte count less than 1.2 cells/μL × 10 3 , which is the lower limit of normal at our institution.
The primary outcome was development of persistent lymphopenia, defined as lymphopenia present on day 4 following sepsis diagnosis. Day 4 was chosen based on previous work from our group demonstrating that septic patients with lymphopenia persisting to day 4 after sepsis diagnosis had increased mortality compared with those whose absolute lymphocyte counts recovered to normal (9) . Secondary outcomes included 28-day mortality, 1-year mortality, ICU length of stay (LOS), and hospital LOS.
Statistical Analysis
Descriptive statistics, including mean (SD) and median (interquartile range [IQR]), were used to describe the patient cohorts. Normality was assessed using histograms and the Kolmogorov-Smirnov test. Baseline characteristics were compared using independent-samples t tests (for normally distributed data), Mann-Whitney U tests (for nonnormally distributed data), or chi-square tests (for categorical data).
Kaplan-Meier survival curves were compared with logrank tests to assess the relationship between hypothermia and 28-day and 1-year mortality. To determine the independent effect of hypothermia on the development of persistent lymphopenia after accounting for multiple confounders, multivariable logistic regression was used to model the odds of lymphopenia on day 4. Hypothermia, age, Acute Physiology and Chronic Health Evaluation (APACHE) II score, and the presence of at least one comorbidity were chosen a priori to be included in the model to control for underlying characteristics which might predispose patients to persistent lymphopenia. Other independent variables were included in the multivariable model if significant at a p value of 0.05 during univariable comparisons of baseline characteristics in patients with and without persistent lymphopenia. Collinearity diagnostics, including variance inflation factors, tolerance statistics, and variance proportions, were evaluated to ensure variable independence.
All statistical tests were carried out using SPSS 21.0 (SPSS, Chicago, IL). All tests were two-tailed and p values less than 0.05 were considered statistically significant.
RESULTS
A total of 445 patients met the inclusion and exclusion criteria during the study period. Sixty-four patients were included in the hypothermic group and 381 patients in the nonhypothermic group. In the hypothermic and nonhypothermic groups, respectively, 23 patients (35.9%) and 87 patients (22.8%) died or were discharged prior to day 4 or did not have complete blood counts sampled on day 4 (detailed in Supplemental  Fig. 1 , Supplemental Digital Content 2, http://links.lww.com/ CCM/B214). This resulted in 41 patients in the hypothermic group and 294 patients in the nonhypothermic group who were available for analysis of persistent lymphopenia. Table 1 reports baseline characteristics and outcomes of the two groups. Hypothermic patients had higher APACHE II scores (median, 20.5 [IQR, 15.0, 27.8] vs 16.0 [13.0, 20.0]; p < 0.001) and a higher incidence of a pulmonary source of bacteremia (29.7% vs 14.7%, p = 0.03). Gram-negative infections occurred in 51.6% of hypothermic patients versus 34.6% of nonhypothermic patients (p = 0.053).
The median absolute lymphocyte count on day 1 was similar between the hypothermic and nonhypothermic groups (0.71 [IQR, 0.48, 1.14] vs 0.66 [0.42, 1.09]; p = 0.52). By day 4, the median absolute lymphocyte count was significantly lower in the hypothermic group (0.82 [IQR, 0.64, 0.97] vs 1.02 [0.68, 1.45]; p = 0.02), and a greater percentage of the hypothermic patients had developed persistent lymphopenia (82.9% vs 59.9%, p = 0.004) ( Table 1) . Hypothermic patients were also more likely to die by day 28 (50.0% vs 24.9%, p < 0.001) and 1 year (60.9% vs 47.0%, p = 0.001) (Kaplan-Meier curves shown in Supplemental Fig. 2 , Supplemental Digital Content 3, http://links.lww.com/CCM/B215). No differences in ICU and hospital LOS were observed between the two groups ( Table 1) .
Comparisons of baseline characteristics in patients who did and did not develop persistent lymphopenia are shown in Supplemental Table 2 (Supplemental Digital Content 4, http://links.lww.com/CCM/B216). Prevalence of hypothermia, APACHE II score, source of bacteremia, and type of organism were significantly different between these two groups. The multivariable analysis to model the odds of developing persistent lymphopenia is shown in Table 2 . Significant predictors of persistent lymphopenia included hypothermia (adjusted odds ratio [OR], 2.70 [95% CI, 1.10, 6.60]; p = 0.03) and APACHE II score (adjusted OR, 1.07 [95% CI, 1.02, 1.13]; p = 0.006). A catheter-related source of bacteremia was protective (adjusted OR, 0.33 [95% CI, 0.13, 0.83], reference pulmonary source, p = 0.02).
DISCUSSION
Persistent lymphopenia is a feature of sepsis-induced immunosuppression and a predictor of mortality in patients with sepsis (9) . This study demonstrates that hypothermic septic patients are more likely to develop persistent lymphopenia. It also confirms the results of previous studies associating hypothermia with short-term mortality (2, 12) and extends the data further by showing an increased risk of death at 1 year. These findings have prognostic and therapeutic implications and suggest areas for further study.
Sepsis-induced immunosuppression contributes to mortality in patients with sepsis by inhibiting pathogen clearance and increasing susceptibility to nosocomial infections (3) . Recent developments in immunostimulatory therapy suggest that these treatments have potential to improve clinical outcomes in patients with sepsis when specifically targeted to patients with quantitative evidence of immune dysfunction (13, 14) .
However, determining which patients are most likely to be immunosuppressed and optimizing timing of these treatments remains a challenge. Identifying early clinical predictors of sepsis-induced immunosuppression, such as hypothermia, could assist physicians in selecting the most appropriate candidates for additional immunological testing in future trials or clinical applications of immunostimulatory therapy.
This study has several limitations. First, a persistently low absolute lymphocyte count is just one feature of sepsis-induced immunosuppression. Sepsis-induced immunosuppression is characterized by numerous alterations in both the adaptive and innate immune systems, including increased immune cell apoptosis, CD4 and CD8 T cell exhaustion, shift from a T helper 1 (T H 1) to T H 2 phenotype, expansion of the regulatory T cell population, decreased human lymphocyte antigen (HLA)-DR expression on antigen presenting cells, impaired phagocytosis, and altered cytokine secretion (3) . As a retrospective analysis, our evaluation of the association between hypothermia and sepsis-induced immunosuppression was restricted to variables acquired during routine clinical care. We could not correlate hypothermia to other markers of immune dysfunction, such as decreased monocyte HLA-DR expression or ex vivo lipopolysaccharide-induced TNF-α levels. A future prospective study will provide insight into the association between hypothermia and these other measures of sepsisinduced immunosuppression.
Second, we cannot demonstrate causality with this retrospective analysis. Consistent with previous studies (2), the hypothermic patients in our study were sicker than the nonhypothermic patients, with significantly higher APACHE II scores. Thus, it is possible that the increased prevalence of persistent lymphopenia in this population was due to increased disease severity. We attempted to control for this by performing a multivariable analysis that included potential confounders, such as age, APACHE II score, comorbidities, and source of sepsis, as additional independent variables.
Third, methods of body temperature measurement were not standardized and not recorded in the electronic medical record from which our data were extracted. Given that most of the patients were diagnosed with sepsis in the emergency department where the usual method of temperature measurement is oral or axillary, we presume that most temperature measurements included in this study were peripheral rather than core. Since peripheral temperatures tend to be slightly lower than core, some patients with borderline hypothermia may have been misallocated to the hypothermic group. However, we were conservative in our definition of hypothermia, choosing a cutoff value of 36.0°C rather than 36.5°C, which was used in other recent studies (2, 12) , so we feel our conclusions are sound.
Finally, this study does not address the impact of warming hypothermic septic patients on clinical outcomes or immune function. All the hypothermic patients included in this study were warmed to normothermia according to institutional protocol. Further optimal management of these patients is yet to be elucidated. 
